Immuron Limited (IMC.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 2.84 Million AUD | 19.79% |
| 2023 | 2.37 Million AUD | 41.28% |
| 2022 | 1.67 Million AUD | 44.94% |
| 2021 | 1.15 Million AUD | 107.44% |
| 2020 | 558.25 Thousand AUD | -53.88% |
| 2019 | 1.21 Million AUD | 50.69% |
| 2018 | 803.33 Thousand AUD | -53.06% |
| 2017 | 1.71 Million AUD | -55.97% |
| 2016 | 3.88 Million AUD | 221.82% |
| 2015 | 1.2 Million AUD | 42.89% |
| 2014 | 845.3 Thousand AUD | -64.51% |
| 2013 | 2.38 Million AUD | 49.95% |
| 2012 | 1.58 Million AUD | 71.18% |
| 2011 | 927.83 Thousand AUD | 113.25% |
| 2010 | 435.1 Thousand AUD | -35.82% |
| 2009 | 677.9 Thousand AUD | -14.16% |
| 2008 | 789.69 Thousand AUD | -39.8% |
| 2007 | 1.31 Million AUD | -5.39% |
| 2006 | 1.38 Million AUD | 27.02% |
| 2005 | 1.09 Million AUD | 31.25% |
| 2004 | 831.69 Thousand AUD | 0.0% |
| 2002 | 253.84 Thousand AUD | -28.75% |
| 2001 | 356.28 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 2.84 Million AUD | 19.79% |
| 2024 Q2 | 2.35 Million AUD | 0.0% |
| 2024 Q4 | 2.84 Million AUD | 0.0% |
| 2023 FY | 2.37 Million AUD | 41.28% |
| 2023 Q2 | 1.83 Million AUD | 0.0% |
| 2023 Q4 | 2.37 Million AUD | 0.0% |
| 2022 Q4 | 1.67 Million AUD | 0.0% |
| 2022 FY | 1.67 Million AUD | 44.94% |
| 2022 Q2 | 1.19 Million AUD | 0.0% |
| 2021 FY | 1.15 Million AUD | 107.44% |
| 2021 Q4 | 1.15 Million AUD | 0.0% |
| 2021 Q2 | 523.05 Thousand AUD | 0.0% |
| 2020 FY | 558.25 Thousand AUD | -53.88% |
| 2020 Q4 | 558.25 Thousand AUD | 0.0% |
| 2020 Q2 | 1.52 Million AUD | 0.0% |
| 2019 Q4 | 1.21 Million AUD | 0.0% |
| 2019 FY | 1.21 Million AUD | 50.69% |
| 2019 Q2 | 521.23 Thousand AUD | 0.0% |
| 2018 Q4 | 803.33 Thousand AUD | 0.0% |
| 2018 FY | 803.33 Thousand AUD | -53.06% |
| 2018 Q2 | 1.17 Million AUD | 0.0% |
| 2017 Q4 | 1.71 Million AUD | 0.0% |
| 2017 FY | 1.71 Million AUD | -55.97% |
| 2017 Q2 | 2.3 Million AUD | 0.0% |
| 2016 FY | 3.88 Million AUD | 221.82% |
| 2016 Q2 | 2.2 Million AUD | 0.0% |
| 2016 Q4 | 3.88 Million AUD | 0.0% |
| 2015 Q4 | 1.2 Million AUD | 0.0% |
| 2015 Q2 | 992.98 Thousand AUD | 0.0% |
| 2015 FY | 1.2 Million AUD | 42.89% |
| 2014 FY | 845.3 Thousand AUD | -64.51% |
| 2014 Q4 | 845.3 Thousand AUD | 0.0% |
| 2014 Q2 | 2.18 Million AUD | 0.0% |
| 2013 Q4 | 2.38 Million AUD | 0.0% |
| 2013 FY | 2.38 Million AUD | 49.95% |
| 2013 Q3 | 2.38 Million AUD | 67.13% |
| 2013 Q2 | 1.42 Million AUD | 0.0% |
| 2013 Q1 | 1.42 Million AUD | -10.28% |
| 2012 Q4 | 1.58 Million AUD | 0.0% |
| 2012 FY | 1.58 Million AUD | 71.18% |
| 2011 Q4 | 927.83 Thousand AUD | 0.0% |
| 2011 FY | 927.83 Thousand AUD | 113.25% |
| 2010 Q4 | 435.1 Thousand AUD | 0.0% |
| 2010 FY | 435.1 Thousand AUD | -35.82% |
| 2009 FY | 677.9 Thousand AUD | -14.16% |
| 2009 Q4 | 677.9 Thousand AUD | 0.0% |
| 2008 FY | 789.69 Thousand AUD | -39.8% |
| 2008 Q4 | 789.69 Thousand AUD | 0.0% |
| 2007 Q4 | 1.31 Million AUD | 0.0% |
| 2007 FY | 1.31 Million AUD | -5.39% |
| 2006 Q4 | 1.38 Million AUD | 0.0% |
| 2006 FY | 1.38 Million AUD | 27.02% |
| 2005 FY | 1.09 Million AUD | 31.25% |
| 2005 Q4 | 1.09 Million AUD | 0.0% |
| 2004 Q4 | 831.69 Thousand AUD | 0.0% |
| 2004 FY | 831.69 Thousand AUD | 0.0% |
| 2002 Q4 | 253.84 Thousand AUD | 0.0% |
| 2002 FY | 253.84 Thousand AUD | -28.75% |
| 2001 Q4 | 356.28 Thousand AUD | 0.0% |
| 2001 FY | 356.28 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 19.817% |
| Acrux Limited | 5.68 Million AUD | 50.052% |
| Actinogen Medical Limited | 1.61 Million AUD | -75.844% |
| AnteoTech Limited | 4.07 Million AUD | 30.298% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -17.052% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -38.115% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -825.708% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 47.647% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 17.109% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -201.689% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -670.947% |
| Biome Australia Limited | 5.37 Million AUD | 47.136% |
| Biotron Limited | 737.5 Thousand AUD | -285.152% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 23.889% |
| BTC Health Limited | 203.94 Thousand AUD | -1292.769% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 77.814% |
| CSL Limited | 27.88 Billion AUD | 99.99% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 65.907% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 89.896% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -142.561% |
| Dimerix Limited | 13.89 Million AUD | 79.554% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 32.835% |
| Hexima Limited | 248.67 Thousand AUD | -1042.287% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -171.658% |
| Immutep Limited | 10.97 Million AUD | 74.129% |
| Imugene Limited | 33.14 Million AUD | 91.43% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -558.093% |
| Memphasys Limited | 5.59 Million AUD | 49.207% |
| Nanollose Limited | 465.64 Thousand AUD | -510.022% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 93.358% |
| Noxopharm Limited | 1.28 Million AUD | -120.433% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -3215.156% |
| Nyrada Inc. | 855.63 Thousand AUD | -231.979% |
| Orthocell Limited | 22.08 Million AUD | 87.137% |
| PharmAust Limited | 896.6 Thousand AUD | -216.808% |
| Patrys Limited | 691.36 Thousand AUD | -310.858% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 20.752% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -74.702% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -22.144% |
| PYC Therapeutics Limited | 10.18 Million AUD | 72.108% |
| Race Oncology Limited | 1.91 Million AUD | -48.22% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 93.643% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 82.128% |
| Starpharma Holdings Limited | 8.69 Million AUD | 67.343% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 98.861% |
| Tissue Repair Ltd | 1.35 Million AUD | -110.268% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 69.641% |